ADPT
Adaptive Biotechnologies Corp
Latest Form 4:Sale$250KbyOWEN KATEY EINTERZ (Director) · filed Aug 28, 2026
Adaptive Biotechnologies Corp (ADPT) has 79 SEC Form 4 filings (247 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Aug 28, 2026.
The most active filer is President and COO RUBINSTEIN JULIE with 39 filings. Insiders have net sold $90.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Chad Robins
- Employees:624
- HQ:Seattle, WA, US
- IPO:2019-06-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$118.7M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Market Cap
$4.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
OWEN KATEY EINTERZFirst filing | Director | Sale | 9,615 | $250K | Aug 28 | SEC ↗ |
| Director | Sale | 30,664 | $748K | Aug 20 | SEC ↗ | |
ROBINS CHAD MFirst in 4 months | CEO and Chairman | Sale | 321,324 | $8.1M | Aug 20 | SEC ↗ |
ROBINS CHAD MFirst in 4 months | CEO and Chairman | Sale | 278,676 | $6.8M | Aug 20 | SEC ↗ |
NEUPERT PETER MFirst filing | Director | Sale | 124,690 | $3.1M | Aug 20 | SEC ↗ |
| Chief Commercial Officer, MRD | Sale | 3,000 | $75K | Aug 12 | SEC ↗ | |
| Chief Commercial Officer, MRD | Sale | 1,299 | $31K | Aug 3 | SEC ↗ | |
| Chief Scientific Officer | Sale | 492,400 | $10.8M | Jul 23 | SEC ↗ | |
| Chief Commercial Officer, MRD | Sale | 5,000 | $115K | Jul 20 | SEC ↗ | |
| Chief People Officer | Sale | 105,762 | $2.4M | Jul 17 | SEC ↗ | |
| Chief Scientific Officer | Sale | 386,240 | $8.5M | Jul 7 | SEC ↗ | |
| Chief People Officer | Sale | 51,004 | $1.1M | Jul 6 | SEC ↗ | |
| Chief People Officer | Sale | 44,838 | $1.0M | Jul 6 | SEC ↗ | |
| Chief Commercial Officer, MRD | Sale | 487 | $11K | Jul 6 | SEC ↗ | |
BENZENO SHARONFirst in 4 months | Chief Commercial Ofc Imm Med | Sale | 11,034 | $232K | Jun 30 | SEC ↗ |
BENZENO SHARONFirst in 4 months | Chief Commercial Ofc Imm Med | Sale | 154,768 | $3.3M | Jun 30 | SEC ↗ |
| Chief Commercial Officer, MRD | Sale | 5,000 | $103K | Jun 29 | SEC ↗ | |
GRIFFIN MICHELLE RENEEFirst in 4 months | Director | Sale | 52,084 | $1.1M | Jun 29 | SEC ↗ |
| Chief Scientific Officer | Sale | 100,000 | $1.7M | Jun 17 | SEC ↗ | |
| Chief Scientific Officer | Sale | 6,160 | $111K | Jun 17 | SEC ↗ | |
| Chief Commercial Officer, MRD | Sale | 5,000 | $95K | Jun 15 | SEC ↗ | |
| Chief People Officer | Sale | 39,741 | $695K | Jun 9 | SEC ↗ | |
| Chief Commercial Officer, MRD | Sale | 11,000 | $198K | Jun 9 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,115 | $41K | May 20 | SEC ↗ | |
| President and COO | Sale | 19,037 | $271K | Apr 29 | SEC ↗ | |
| President and COO | Sale | 19,060 | $269K | Apr 24 | SEC ↗ | |
| President and COO | Sale | 19,060 | $262K | Apr 24 | SEC ↗ | |
| President and COO | Sale | 19,060 | $267K | Apr 24 | SEC ↗ | |
| President and COO | Sale | 19,060 | $278K | Apr 21 | SEC ↗ | |
| President and COO | Sale | 19,060 | $277K | Apr 21 | SEC ↗ | |
| President and COO | Sale | 30,941 | $454K | Apr 21 | SEC ↗ | |
| President and COO | Sale | 19,060 | $278K | Apr 16 | SEC ↗ | |
| President and COO | Sale | 19,060 | $278K | Apr 16 | SEC ↗ | |
| President and COO | Sale | 19,060 | $270K | Apr 16 | SEC ↗ | |
| President and COO | Sale | 19,060 | $264K | Apr 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $243K | Apr 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $251K | Apr 13 | SEC ↗ | |
| Chief People Officer | Sale | 22,564 | $340K | Apr 10 | SEC ↗ | |
| Chief Scientific Officer | Sale | 10,000 | $149K | Apr 10 | SEC ↗ | |
| President and COO | Sale | 19,060 | $273K | Apr 8 | SEC ↗ | |
| President and COO | Sale | 19,060 | $258K | Apr 8 | SEC ↗ | |
| President and COO | Sale | 30,941 | $459K | Apr 8 | SEC ↗ | |
| CEO and Chairman | Sale | 83,332 | $1.2M | Apr 8 | SEC ↗ | |
| CEO and Chairman | Sale | 37,263 | $566K | Apr 8 | SEC ↗ | |
| President and COO | Sale | 19,060 | $275K | Apr 2 | SEC ↗ | |
| President and COO | Sale | 19,060 | $278K | Apr 2 | SEC ↗ | |
| President and COO | Sale | 19,060 | $254K | Mar 31 | SEC ↗ | |
| President and COO | Sale | 19,060 | $241K | Mar 31 | SEC ↗ | |
| President and COO | Sale | 19,060 | $256K | Mar 31 | SEC ↗ | |
| President and COO | Sale | 19,060 | $261K | Mar 26 | SEC ↗ | |
| President and COO | Sale | 19,060 | $272K | Mar 26 | SEC ↗ | |
| President and COO | Sale | 19,060 | $269K | Mar 26 | SEC ↗ | |
| President and COO | Sale | 19,060 | $251K | Mar 23 | SEC ↗ | |
| President and COO | Sale | 19,060 | $255K | Mar 23 | SEC ↗ | |
| President and COO | Sale | 19,060 | $264K | Mar 23 | SEC ↗ | |
| President and COO | Sale | 19,060 | $256K | Mar 18 | SEC ↗ | |
| President and COO | Sale | 19,060 | $255K | Mar 18 | SEC ↗ | |
| President and COO | Sale | 19,060 | $251K | Mar 18 | SEC ↗ | |
| President and COO | Sale | 141,583 | $1.9M | Mar 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $245K | Mar 13 | SEC ↗ | |
| President and COO | Sale | 19,060 | $247K | Mar 13 | SEC ↗ | |
| Chief People Officer | Sale | 30,593 | $431K | Mar 13 | SEC ↗ | |
| CEO and Chairman | Sale | 470,167 | $6.2M | Mar 13 | SEC ↗ | |
| Director | Sale | 15,394 | $214K | Mar 13 | SEC ↗ | |
| Chief Scientific Officer | Sale | 470,266 | $6.2M | Mar 13 | SEC ↗ | |
BOBULSKY SUSANFirst filing | Chief Commercial Officer, MRD | Sale | 41,338 | $544K | Mar 13 | SEC ↗ |
| Chief Financial Officer | Sale | 18,672 | $246K | Mar 13 | SEC ↗ | |
BENZENO SHARONFirst in 3 months | Chief Commercial Ofc Imm Med | Sale | 63,103 | $831K | Mar 13 | SEC ↗ |
| President and COO | Sale | 30,941 | $468K | Mar 10 | SEC ↗ | |
| President and COO | Sale | 30,941 | $458K | Mar 10 | SEC ↗ | |
| President and COO | Sale | 19,460 | $286K | Mar 10 | SEC ↗ | |
| Chief People Officer | Sale | 38,074 | $575K | Mar 9 | SEC ↗ | |
RUBINSTEIN JULIEFirst filing | President and COO | Sale | 30,941 | $485K | Mar 5 | SEC ↗ |
RUBINSTEIN JULIEFirst filing | President and COO | Sale | 30,941 | $514K | Mar 5 | SEC ↗ |
RUBINSTEIN JULIEFirst filing | President and COO | Sale | 30,941 | $495K | Mar 5 | SEC ↗ |
GRIFFIN MICHELLE RENEEFirst filing | Director | Sale | 48,044 | $735K | Mar 5 | SEC ↗ |
| Chief Scientific Officer | Sale | 10,000 | $157K | Mar 4 | SEC ↗ | |
| Chief Scientific Officer | Sale | 14,233 | $235K | Mar 4 | SEC ↗ | |
| CEO and Chairman | Sale | 182,891 | $2.9M | Mar 3 | SEC ↗ | |
| CEO and Chairman | Sale | 289,024 | $4.6M | Mar 3 | SEC ↗ | |
| CEO and Chairman | Sale | 53,083 | $824K | Mar 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,145 | $40K | Feb 6 | SEC ↗ | |
| Chief Scientific Officer | Sale | 34,668 | $645K | Feb 4 | SEC ↗ | |
| Chief Scientific Officer | Sale | 8,120 | $154K | Feb 4 | SEC ↗ | |
| CEO and Chairman | Sale | 124,998 | $2.3M | Feb 4 | SEC ↗ | |
| Chief People Officer | Sale | 79,590 | $1.4M | Jan 14 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,290 | $77K | Jan 14 | SEC ↗ | |
| Chief Scientific Officer | Sale | 10,000 | $164K | Jan 8 | SEC ↗ | |
| Chief People Officer | Sale | 4,394 | $77K | Jan 7 | SEC ↗ | |
| CEO and Chairman | Sale | 124,998 | $1.9M | Jan 7 | SEC ↗ | |
| Chief People Officer | Sale | 3,125 | $50K | Jan 6 | SEC ↗ | |
LO FRANCISFirst filing | Chief People Officer | Sale | 113,890 | $1.8M | Dec 17 | SEC ↗ |
HERSHBERG ROBERTFirst filing | Director | Sale | 22,968 | $367K | Dec 12 | SEC ↗ |
| Chief Commercial Ofc Imm Med | Sale | 12,604 | $212K | Dec 8 | SEC ↗ | |
| Chief Scientific Officer | Sale | 27,212 | $506K | Dec 5 | SEC ↗ | |
| Chief Scientific Officer | Sale | 10,000 | $166K | Dec 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 162,820 | $3.2M | Dec 2 | SEC ↗ | |
| CEO and Chairman | Sale | 35,736 | $703K | Dec 1 | SEC ↗ | |
| CEO and Chairman | Sale | 124,998 | $2.4M | Dec 1 | SEC ↗ | |
BENZENO SHARONFirst filing | Chief Commercial Ofc Imm Med | Sale | 297,925 | $4.9M | Nov 24 | SEC ↗ |
BENZENO SHARONFirst filing | Chief Commercial Ofc Imm Med | Sale | 308,477 | $5.2M | Nov 24 | SEC ↗ |
PISKEL KYLEFirst filing | Chief Financial Officer | Sale | 238 | $3K | Nov 18 | SEC ↗ |
ROBINS CHAD MFirst filing | CEO and Chairman | Sale | 86,161 | $1.3M | Nov 12 | SEC ↗ |
ROBINS CHAD MFirst filing | CEO and Chairman | Sale | 1,237 | $18K | Nov 12 | SEC ↗ |
ROBINS CHAD MFirst filing | CEO and Chairman | Sale | 1,867 | $28K | Nov 12 | SEC ↗ |
ROBINS HARLAN SFirst filing | Chief Scientific Officer | Sale | 10,000 | $148K | Nov 12 | SEC ↗ |
Related companies
Adaptive Biotechnologies Corp is in the Healthcare sector.